BerGenBio

Share Issue/Capital Change • Aug 28, 2019

BerGenBio ASA: Increase of share capital, exercise of share options and primary insider notification

BerGenBio ASA: Increase of share capital, exercise of share options and primary insider notification

Bergen, Norway, 28 August 2019. The Board of Directors of BerGenBio ASA (the

"Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the

share option agreements and in accordance with the authorisation granted by the

general meeting on 13 March 2019, resolved to increase the Company's share

capital by NOK 54,000 by issuance of 540,000 new shares. The new shares are

subscribed for by option owners that wish, and are entitled, to exercise options

in accordance with the Company's option scheme. The subscription price is in

accordance with the prevailing options price pursuant to the Company´s option

scheme, an average NOK 8.39 per share. Options which have been exercised have

been granted between 2010 and 2012 and all options will expire in 2019 if not

exercised.

Out of the total number of exercised share options, 225,000 share options at an

average strike price at NOK 8.15 were exercised by primary insider Richard

Godfrey (CEO). Richard Godfrey has transferred his rights to receive shares

resulting from the exercise of options to a third party to cover all cost

related to the exercise and will keep the remaining shares from the exercise.

The sales amount will be finally determined on the basis of the price

subsequently obtained by the third party when selling the shares in the market.

Final compensation for the transferred rights and number of shares received from

the transaction will be reported when known. After exercising options, Richard

Godfrey holds 1,129,284 unexercised options in the Company. As of today, Richard

Godfrey holds 167,815 shares in the Company through Gnist Holding AS.

Out of the total number of exercised share options, 150,000 share options at an

average strike price at NOK 8.45 were exercised by primary insider James Lorens,

CSO. James Lorens has transferred his rights to receive shares resulting from

the exercise of options to a third party to cover all cost related to the

exercise and will keep the remaining shares from the exercise. The sales amount

will be finally determined on the basis of the price subsequently obtained by

the third party when selling the shares in the market. Final compensation for

the transferred rights and number of shares received from the transaction will

be reported when known. After exercising options, James Lorens holds 588,507

unexercised options in the Company. As of today, James Lorens holds 250,000

shares in the Company.

Out of the total number of exercised share options, 15,000 share options at an

average strike price at NOK 10.62 were exercised by primary insider Endre

Kjærland, Associate Director of IP and Contracts. Endre Kjærland has transferred

his rights to receive shares resulting from the exercise of options to a third

party to cover all cost related to the exercise and will keep the remaining

shares from the exercise. The sales amount will be finally determined on the

basis of the price subsequently obtained by the third party when selling the

shares in the market. Final compensation for the transferred rights and number

of shares received from the transaction will be reported when known. After

exercising options, Endre Kjærland holds 88,525 unexercised options in the

Company. As of today, Endre Kjærland holds 1,508 shares in the Company.

The capital increase is expected to be registered within 7 days, and following

the issuance of the new shares, the issued share capital of BerGenBio ASA will

be NOK 6,107,659 consisting of 61,076,590 shares, each with a par value of NOK

0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the

expectations expressed or implied in this announcement by such forward-looking

statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.